Yatiri Bio Inc. is pleased to announce that Professor John Yates from The Scripps Research Institute has joined Yatiri Bio as an advisory board member. Professor Yates is a pioneer in the field of proteomics and his expertise in…
The molecular and biological heterogeneity of AML poses significant challenges to the discovery of novel agents and therapeutic positioning. Currently, researchers utilize cell lines as ex vivo models to discover novel compounds. Additionally, investigators have coupled genomic and transcriptomic…
FLT3-mutated AML accounts for about 30% of newly diagnosed adult AML cases and is associated with aggressive disease and a high risk of relapse. The introduction of FLT3 inhibitors, such as midostaurin, gilteritinib, and quizartinib, in combination with standard…
Acute myeloid leukemia (AML) is a deadly blood cancer with poor long-term survival, and relapse/refractory AML remains a major clinical challenge, with overall survival rates of less than 30% at one year. Early clinical data from NCT04891757 demonstrate evidence…
Broad coverage of the plasma proteome with MS has become accessible through particle-based enrichments that reduces the dynamic range enhancing the detection of low-abundance proteins. The Mag-Net method enriches for membrane-bound particles such as extracellular vesicles, detecting >5,000 proteins…
Acute myeloid leukemia (AML) is a deadly blood cancer with poor long-term survival, and current treatments often fail due to relapse and limitations in model accuracy. To better reflect disease heterogeneity, we developed a diverse panel of patient-derived AML…
Current AML cell lines do not predict drug sensitivity because the cell lines harbor strong driver alterations that occur in only a small fraction of patients, and their biology has drifted from that of an AML patient. Leveraging our…
Acute myeloid leukemia (AML) is a deadly blood cancer with poor long-term survival, and current treatments often fail due to relapse and limited model accuracy. To better capture disease heterogeneity, we developed a diverse panel of patient-derived AML models.…